December 02, 2022 Burned by Palforzia, Nestlé retreats from its pharma experiment The chocolate-to-vitamins giant discovers that launching a drug is hard. Should its biopharma partners be worried?
October 06, 2022 SITC 2022 preview – cytokines and oral checkpoints Recently unveiled abstract titles for next month's SITC conference reveal new competition for Incyte’s small-molecule PD-L1 inhibitors.
January 05, 2021 Hope versus experience in glioblastoma Development of new drugs for this hard-to-treat brain cancer is a slow and incremental process.